Cat. No：GM-C26215
Product：ADCP FcγRIIb Jurkat Effector Cell Line
Cat. No：GM-C26215
Product：ADCP FcγRIIb Jurkat Effector Cell Line
Cell Growth Medium：RPMI 1640+10% FBS+1% P.S+3.5 μg/mL Blasticidin+0.75 μg/mL Puromycin
Cell Freezing Medium：90% FBS+10% DMSO
Assay Buffer：RPMI 1640+1% FBS+1% P.S
ADCP, or Antibody-Dependent Cell-Mediated Cytotoxicity, refers to the process where immune cells expressing Fc receptors engulf target cells by recognizing the Fc portion of antibodies binding to the target cell. Nowadays, the ADCP mechanism is utilized for detecting and assessing the potency of antibodies. When the antibody's Fab segment binds to the target antigen on the cell surface, and the antibody's Fc segment simultaneously binds to the FcγRIIb receptor on effector cells (mainly macrophages), crosslinking occurs, activating the ADCP pathway leading to target cell engulfment. In the traditional ADCP biological activity assay, macrophages from donors are used as effector cells, which exhibit considerable response variability, making them difficult to prepare and leading to high background readings.
The Genomeditech's ADCP FcγRIIb Jurkat Effector Cell Line uses engineered Jurkat cells as effector cells. Through clever vector design and a third-generation lentivirus reporter gene system, it stably expresses human FcγRIIb receptor and firefly luciferase driven by a transcription factor to quantify the biological activity of antibodies in the ADCP mechanism activated through the NFAT pathway, with luciferase production, and the luciferase activity in effector cells quantified through bioluminescence readings. This method provides high signal values with low background levels. Custom ADCP cell lines and ADCP activity testing services are also available.
| FcγR | ||
| Cynomolgus_FcRn MDCK Cell Line | H_FCGR1A(CD64) CHO-K1 Cell Line | H_FCGR1A(CD64) HEK-293 Cell Line |
| H_FCGR2A(CD32A) CHO-K1 Cell Line | H_FCGR2B(CD32B) CHO-K1 Cell Line | H_FCGR3A(CD16a) 158F CHO-K1 Cell Line |
| H_FCGR3A(CD16a) 158V CHO-K1 Cell Line | H_FCGR3B(CD16b) CHO-K1 Cell Line | H_FcRn CHO-K1 Cell Line |
| H_FcRn MDCK Cell Line | Mouse_FcRn MDCK Cell Line | |
| Anti-FcRn hIgG4 Reference Antibody(Rozabio) | Anti-H_FcRn IgG4 Antibody(Rozanolixizumab) | Anti-Mouse CD1632 mIgG2b Antibody(2.4G2) |
| ADCCP | ||
| ADCC FcγRIIIa(158F) Jurkat Effector Cell Line | ADCC FcγRIIIa(158V) DDX35TM Jurkat Effector Cell Line | ADCC FcγRIIIa(158V) Jurkat Effector Cell Line |
| ADCC M_FcγRIV Jurkat Effector Cell Line | ADCP FcγRI Jurkat Effector Cell Line | ADCP FcγRIIa DDX35TM Jurkat Effector Cell Line |
| ADCP FcγRIIa Jurkat Effector Cell Line | ADCP FcγRIIa R131 Jurkat Effector Cell Line | |
Cat. No：GM-C26215
Product：ADCP FcγRIIb Jurkat Effector Cell Line
Cell Growth Medium：RPMI 1640+10% FBS+1% P.S+3.5 μg/mL Blasticidin+0.75 μg/mL Puromycin
Cell Freezing Medium：90% FBS+10% DMSO
Assay Buffer：RPMI 1640+1% FBS+1% P.S
ADCP, or Antibody-Dependent Cell-Mediated Cytotoxicity, refers to the process where immune cells expressing Fc receptors engulf target cells by recognizing the Fc portion of antibodies binding to the target cell. Nowadays, the ADCP mechanism is utilized for detecting and assessing the potency of antibodies. When the antibody's Fab segment binds to the target antigen on the cell surface, and the antibody's Fc segment simultaneously binds to the FcγRIIb receptor on effector cells (mainly macrophages), crosslinking occurs, activating the ADCP pathway leading to target cell engulfment. In the traditional ADCP biological activity assay, macrophages from donors are used as effector cells, which exhibit considerable response variability, making them difficult to prepare and leading to high background readings.
The Genomeditech's ADCP FcγRIIb Jurkat Effector Cell Line uses engineered Jurkat cells as effector cells. Through clever vector design and a third-generation lentivirus reporter gene system, it stably expresses human FcγRIIb receptor and firefly luciferase driven by a transcription factor to quantify the biological activity of antibodies in the ADCP mechanism activated through the NFAT pathway, with luciferase production, and the luciferase activity in effector cells quantified through bioluminescence readings. This method provides high signal values with low background levels. Custom ADCP cell lines and ADCP activity testing services are also available.
| FcγR | ||
| Cynomolgus_FcRn MDCK Cell Line | H_FCGR1A(CD64) CHO-K1 Cell Line | H_FCGR1A(CD64) HEK-293 Cell Line |
| H_FCGR2A(CD32A) CHO-K1 Cell Line | H_FCGR2B(CD32B) CHO-K1 Cell Line | H_FCGR3A(CD16a) 158F CHO-K1 Cell Line |
| H_FCGR3A(CD16a) 158V CHO-K1 Cell Line | H_FCGR3B(CD16b) CHO-K1 Cell Line | H_FcRn CHO-K1 Cell Line |
| H_FcRn MDCK Cell Line | Mouse_FcRn MDCK Cell Line | |
| Anti-FcRn hIgG4 Reference Antibody(Rozabio) | Anti-H_FcRn IgG4 Antibody(Rozanolixizumab) | Anti-Mouse CD1632 mIgG2b Antibody(2.4G2) |
| ADCCP | ||
| ADCC FcγRIIIa(158F) Jurkat Effector Cell Line | ADCC FcγRIIIa(158V) DDX35TM Jurkat Effector Cell Line | ADCC FcγRIIIa(158V) Jurkat Effector Cell Line |
| ADCC M_FcγRIV Jurkat Effector Cell Line | ADCP FcγRI Jurkat Effector Cell Line | ADCP FcγRIIa DDX35TM Jurkat Effector Cell Line |
| ADCP FcγRIIa Jurkat Effector Cell Line | ADCP FcγRIIa R131 Jurkat Effector Cell Line | |
